190141-99-2

Basic information

• Product Name: 1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester(9CI)
• Synonyms: 1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester(9CI);tert-Butyl 3-aMino-4-hydroxypyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 3-aMino-4-hydroxy-, 1,1-diMethylethyl ester;3-Amino-4-hydroxy-1-pyrrolidinecarboxylic acid tert-butyl ester;tert-Butyl 3-amino-4-hydroxy-1-pyrrolidinecarboxylate;[trans-]-3-amino-4-hydroxy-1-pyrrolidinecarboxylic acid 1,1-dimethylethyl ester;2-Methyl-2-propanyl 3-amino-4-hydroxy-1-pyrrolidinecarboxylate;3-Amino-4-Hydroxy-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester(Mixture Of Cis&Trans)
• CAS NO: 190141-99-2
• Molecular Formula: C₉H₁₈N₂O₃
• Molecular Weight: 202.26
• Product Categories: AMINOACID
• Mol File: 190141-99-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 309℃
• Flash Point: 141℃
• Appearance: /
• Density: 1.179
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.36±0.40(Predicted)
• CAS DataBase Reference: 1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester(9CI)(190141-99-2)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester(9CI)(190141-99-2)

Safety Data

• Hazardous Substances Data: 190141-99-2(Hazardous Substances Data)

Usage

General Description

1-Pyrrolidinecarboxylic acid, 3-amino-4-hydroxy-, 1,1-dimethylethyl ester (9CI) is a chemical compound that falls under the category of amino acids. It is a derivative of pyrrolidinecarboxylic acid and is commonly known as N-tert-butoxycarbonyl-3-amino-4-hydroxy-l-proline. 1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester(9CI) is often used in the synthesis of peptides and pharmaceuticals due to its ability to serve as a building block for various bioactive molecules. It has also been studied for its potential in drug development and as a pharmaceutical intermediate. Additionally, it exhibits potential anti-cancer and anti-inflammatory properties, making it an area of interest for further research and development in the medical and pharmaceutical industries.

Upstream product

• 203434-45-1 (±)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 

Downstream Products

• 1215485-03-2 3,4-diaminopyrrolidinyl-1-carboxylic acid tert-butyl ester 
• 1215210-04-0 (3S,4S)-3-amino-4-hydroxypyrrolidine dihydrochloride 
• 1247884-24-7 tert-butyl 3-(3-cyanobenzamido)-4-hydroxypyrrolidine-1-carboxylate 
• 190142-00-8 (3R,S)-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-(4R,S)-4-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Guanidine derivative and application thereof

The invention relates to a guanidine derivative serving as a VAP-1 inhibitor and application of the guanidine derivative, and further relates to a pharmaceutical composition containing the compound. The compound or the pharmaceutical composition can be us

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in p